Tradestie Institutional Equity Comparison Engine
SLS vs BOLD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SLS Overall Edge
SLS Captures Institutional Edge (2โ0 Pillars ยท 2โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SELLAS Life Sciences Group, Inc. Common Stock (SLS) driven by superior Momentum & Technical, Options & Structure. Fundamentally, SLS trades at N/M Forward P/E with 0.0% operating margin (-82.5% YoY revenue) versus BOLD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SLS sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SLS N/M vs BOLD N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -82.5% vs +0.0%
Momentum & Technical Winner
SLS
1Y +798.7% vs +101.7% ยท 52W Pos 52% vs 62%
Options & Structure Winner
SLS
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
SLS
NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$13.66
-8.08% 1D
Market Cap
$3.0B
1M Return
+20.35%
1Y Return
+798.68%
Forward P/E
N/M
Unified AI Score
33.6 / 100
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 48.9
BOLD
NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap
$56.2M
1M Return
-4.92%
1Y Return
+101.74%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 25.0
Fund 50.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SLS +798.68%
BOLD +101.74%
Spread: +696.94 pp (SLS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SLS TTM Op. Margin: 0.0%
BOLD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLS vs BOLD. Trailing 12-month operating profitability (SLS 0.0% vs BOLD 0.0%) and valuation multiples (SLS N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SLS | BOLD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $56.2M | Larger Scale | SLS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -82.5% | +0.0% | Higher Growth | BOLD |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -40.3% | -64.6% | Higher ROE | SLS |
| 52-Week Range Position Momentum | 52% ($1โ$25) | 62% ($1โ$3) | Stronger Trend | BOLD |
| Beta / 30D Volatility Risk Regime | 1.91ฮฒ ยท 550% Vol | -0.08ฮฒ ยท 28% Vol | Lower Realized Risk | BOLD |
| Unified Institutional Score Composite Signal | 33.6 / 100 (SELL) | 36.8 / 100 (SELL) | Higher Composite | BOLD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SLS vs BOLD Buy Guide
SLS
CONSOLIDATION
102d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
BOLD
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SLS nor BOLD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.